Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537907 | 0.73 | HPGD (0.38) | PARP1MAPTNPC1RAB9AKDM4E | |
| SCHEMBL23796440 | 0.73 | NOS1 (0.40) | MAPTKDM4EKMT2A | |
| SCHEMBL4684391 | 0.69 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4684388 | 0.69 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4684386 | 0.69 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4684389 | 0.69 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4684384 | 0.69 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4935604 | 0.69 | GPR3 (0.35) | MAPTKDM4E | |
| SCHEMBL15630922 | 0.69 | GPR3 (0.35) | MAPTKDM4E | |
| SCHEMBL4935598 | 0.69 | GPR3 (0.35) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | PARP1 360/4885MAPT 2073/4885NPC1 1261/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | PARP1 360/4885MAPT 2073/4885NPC1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.